Inhibiting immune escape in lung adenocarcinoma: the role of SPARC in suppressing CD276 function

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):1–14. doi: 10.3322/caac.21660.
   Web of Science ®Google Scholar
• Chen P, Liu Y, Wen Y, et al. Non-small cell lung cancer in China. Cancer Commun. 2022;42(10):937–970. doi: 10.1002/cac2.12359.
   PubMed Web of Science ®Google Scholar
• Hofmarcher T, Lindgren P, Wilking N. Systemic anti-cancer therapy patterns in advanced non-small cell lung cancer in Europe. J Cancer Policy. 2022;34:100362. doi: 10.1016/j.jcpo.2022.100362.
   PubMed Web of Science ®Google Scholar
• Li XY, Su LX, Chen WX, et al. Clinical implications of necroptosis genes expression for cancer immunity and prognosis: a pan-cancer analysis. Front Immunol. 2022;13:882216. doi: 10.3389/fimmu.2022.882216.
   PubMed Web of Science ®Google Scholar
• Passarelli A, Aieta M, Sgambato A, et al. Targeting immunometabolism mediated by CD73 pathway in EGFR-mutated non-small cell lung cancer: a new hope for overcoming immune resistance. Front Immunol. 2020;11:1479. doi: 10.3389/fimmu.2020.01479.
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–1437. doi: 10.1038/nm.3394.
   PubMed Web of Science ®Google Scholar
• Genova C, Dellepiane C, Carrega P, et al. Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade. Front Immunol. 2021;12:799455. doi: 10.3389/fimmu799455.
   PubMed Web of Science ®Google Scholar
• Wong KY, Cheung AH-K, Chen B, et al. Cancer-associated fibroblasts in nonsmall cell lung cancer: from molecular mechanisms to clinical implications. Int J Cancer. 2022;151(8):1195–1215. doi: 10.1002/ijc.34127.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–1022. doi: 10.1038/ni.2703.
   PubMed Web of Science ®Google Scholar
• Kang I, Yoon DW, Braun KR, et al. Expression of versican V3 by arterial smooth muscle cells alters tumor growth factor β (TGF β)-, epidermal growth factor (EGF)-, and nuclear factor κB (NFκB)-dependent signaling pathways, creating a microenvironment that resists monocyte adhesion. J Biol Chem. 2014;289(22):15393–15404. doi: 10.1074/jbc.M113.544338.
   PubMed Web of Science ®Google Scholar
• Bussard KM, Mutkus L, Stumpf K, et al. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res. 2016;18(1):84. doi: 10.1186/s13058-016-0740-2.
   PubMed Web of Science ®Google Scholar
• Gentles AJ, Hui AB, Feng W, et al. A human lung tumor microenvironment interactome identifies clinically relevant cell-type cross-talk. Genome Biol. 2020;21(1):107. doi: 10.1186/s13059-020-02019-x.
   PubMed Web of Science ®Google Scholar
• Mamdani H, Matosevic S, Khalid AB, et al. Immunotherapy in lung cancer: current landscape and future directions. Front Immunol. 2022;13:823618. doi: 10.3389/fimmu.2022.823618.
   PubMed Web of Science ®Google Scholar
• Tian Y, Zhai X, Yan W, et al. Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC. Cancer Med. 2021;10(1):3–14. doi: 10.1002/cam4.3590.
   PubMed Web of Science ®Google Scholar
• Tai IT, Tang MJ. SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat. 2008;11(6):231–246. doi: 10.1016/j.drup.2008.08.005.
   PubMed Web of Science ®Google Scholar
• Porter PL, Sage EH, Lane TF, et al. Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem. 1995;43(8):791–800. doi: 10.1177/43.8.7622842.
   PubMed Web of Science ®Google Scholar
• Li T, Tan X, Zhu S, et al. SPARC induces phenotypic modulation of human brain vascular smooth muscle cells via AMPK/mTOR-mediated autophagy. Neurosci Lett. 2019;712:134485. doi: 10.1016/j.neulet.2019.134485.
   PubMed Web of Science ®Google Scholar
• Chen S, Zou Q, Chen Y, et al. Regulation of SPARC family proteins in disorders of the Central nervous system. Brain Res Bull. 2020;163:178–189. doi: 10.1016/j.brainresbull.2020.05.005.
   PubMed Web of Science ®Google Scholar
• Nagaraju GPC, Sharma D. Anti-cancer role of SPARC, an inhibitor of adipogenesis. Cancer Treat Rev. 2011;37(7):559–566. doi: 10.1016/j.ctrv.2010.12.001.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang Y, Tan Y, et al. Clinical significance of SPARC in esophageal squamous cell carcinoma. Biochem Biophys Res Commun. 2017;492(2):184–191. doi: 10.1016/j.bbrc.2017.08.043.
   PubMed Web of Science ®Google Scholar
• Feng J, Tang L. SPARC in tumor pathophysiology and as a potential therapeutic target. Curr Pharm Des. 2014;20(39):6182–6190. doi: 10.2174/1381612820666140619123255.
   PubMed Web of Science ®Google Scholar
• Arnold SA, Brekken RA. SPARC: a matricellular regulator of tumorigenesis. J Cell Commun Signal. 2009;3(3-4):255–273. doi: 10.1007/s12079-009-0072-4.
   PubMed Web of Science ®Google Scholar
• Chlenski A, Cohn SL. Modulation of matrix remodeling by SPARC in neoplastic progression. Semin Cell Dev Biol. 2010;21(1):55–65. doi: 10.1016/j.semcdb.2009.11.018.
   PubMed Web of Science ®Google Scholar
• Neuzillet C, Tijeras-Raballand A, Cros J, et al. Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer Metastasis Rev. 2013;32(3-4):585–602. doi: 10.1007/s10555-013-9439-3.
   PubMed Web of Science ®Google Scholar
• Shin M, Mizokami A, Kim J, et al. Exogenous SPARC suppresses proliferation and migration of prostate cancer by interacting with integrin beta1. Prostate. 2013;73(11):1159–1170. doi: 10.1002/pros.22664.
   PubMed Web of Science ®Google Scholar
• Ma J, Gao S, Xie X, et al. SPARC inhibits breast cancer bone metastasis and may be a clinical therapeutic target. Oncol Lett. 2017;14(5):5876–5882. doi: 10.3892/ol.2017.6925.
   PubMed Web of Science ®Google Scholar
• Chlenski A, Guerrero LJ, Peddinti R, et al. Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors. Mol Cancer. 2010;9(1):138. doi: 10.1186/1476-4598-9-138.
   PubMedGoogle Scholar
• Huang Y, Zhang J, Zhao Y-Y, et al. SPARC expression and prognostic value in non-small cell lung cancer. Chin J Cancer. 2012;31(11):541–548. doi: 10.5732/cjc.012.10212.
   PubMedGoogle Scholar
• Zhao B, Li H, Xia Y, et al. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy. J Hematol Oncol. 2022;15(1):153. doi: 10.1186/s13045-022-01364-7.
   PubMed Web of Science ®Google Scholar
• Feng R, Chen Y, Liu Y, et al. The role of B7-H3 in tumors and its potential in clinical application. Int Immunopharmacol. 2021;101(Pt B):108153. doi: 10.1016/j.intimp.2021.108153.
   PubMedGoogle Scholar
• Getu AA, Tigabu A, Zhou M, et al. New frontiers in ­immune checkpoint B7-H3 (CD276) research and drug development. Mol Cancer. 2023;22(1):43. doi: 10.1186/023-01751-9.
   PubMed Web of Science ®Google Scholar
• Zhou W-T, Jin W-L. B7-H3/CD276: an emerging cancer immunotherapy. Front Immunol. 2021;12:701006. doi: 10.3389/fimmu.2021.701006.
   PubMed Web of Science ®Google Scholar
• Wu S, Zhao X, Wu S, et al. Overexpression of B7-H3 correlates with aggressive clinicopathological characteristics in non-small cell lung cancer. Oncotarget. 2016;7(49):81750–81756. doi: 10.18632/oncotarget.13177.
   PubMedGoogle Scholar
• Malapelle U, Parente P, Pepe F, et al. B7-H3/CD276 inhibitors: is there room for the treatment of metastatic non-small cell lung cancer? Int J Mol Sci. 2022;23(24):16077. doi: 10.3390/ijms232416077.
   PubMed Web of Science ®Google Scholar
• Yang S, Wei W, Zhao Q. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. Int J Biol Sci. 2020;16(11):1767–1773. doi: 10.7150/ijbs.41105.
   PubMed Web of Science ®Google Scholar
• Wong SLI, Sukkar MB. The SPARC protein: an overview of its role in lung cancer and pulmonary fibrosis and its potential role in chronic airways disease. Br J Pharmacol. 2017;174(1):3–14. doi: 10.1111/bph.13653.
   PubMed Web of Science ®Google Scholar
• Liu S, Liang J, Liu Z, et al. The role of CD276 in cancers. Front Oncol. 2021;11:654684. doi: 10.3389/fonc.2021.654684.
   PubMedGoogle Scholar
• Kontos F, Michelakos T, Kurokawa T, et al. B7-H3: an attractive target for antibody-based immunotherapy. Clin Cancer Res. 2021;27(5):1227–1235. doi: 10.1158/1078-0432.Ccr-20-2584.
   PubMed Web of Science ®Google Scholar